BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 31996097)

  • 1. Utilities of
    Guan H; Toraldo G; Cerda S; Godley FA; Rao SR; McAneny D; Doherty G; Braverman L; Lee SL
    Thyroid; 2020 Apr; 30(4):536-547. PubMed ID: 31996097
    [No Abstract]   [Full Text] [Related]  

  • 2. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
    An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
    Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.
    Halászlaki C; Tóbiás B; Balla B; Kósa JP; Horányi J; Bölöny E; Nagy Z; Speer G; Járay B; Székely E; Istók R; Székely T; Putz Z; Dank M; Lakatos P; Takács I
    Endocr Pract; 2016 Sep; 22(9):1081-7. PubMed ID: 27214302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytological features and nuclear scores: Diagnostic tools in preoperative fine needle aspiration of indeterminate thyroid nodules with RAS or BRAF K601E mutations?
    Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
    Cytopathology; 2021 Jan; 32(1):37-44. PubMed ID: 32803788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology.
    Macerola E; Rago T; Proietti A; Basolo F; Vitti P
    J Endocrinol Invest; 2019 Feb; 42(2):157-166. PubMed ID: 29704233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The variable phenotype and low-risk nature of RAS-positive thyroid nodules.
    Medici M; Kwong N; Angell TE; Marqusee E; Kim MI; Frates MC; Benson CB; Cibas ES; Barletta JA; Krane JF; Ruan DT; Cho NL; Gawande AA; Moore FD; Alexander EK
    BMC Med; 2015 Aug; 13():184. PubMed ID: 26253102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules: A prospective blinded single center study in China.
    Song Y; Xu G; Ma T; Zhu Y; Yu H; Yu W; Wei W; Wang T; Zhang B
    Cancer Med; 2020 Nov; 9(22):8397-8405. PubMed ID: 32976686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules.
    Marcadis AR; Valderrabano P; Ho AS; Tepe J; Swartzwelder CE; Byrd S; Sacks WL; Untch BR; Shaha AR; Xu B; Lin O; Ghossein RA; Wong RJ; Marti JL; Morris LGT
    Surgery; 2019 Jan; 165(1):17-24. PubMed ID: 30360906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of ThyroSeq Results with Surgical Histopathology in Cytologically Indeterminate Thyroid Nodules.
    Chin PD; Zhu CY; Sajed DP; Fishbein GA; Yeh MW; Leung AM; Livhits MJ
    Endocr Pathol; 2020 Dec; 31(4):377-384. PubMed ID: 32671653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
    Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
    JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
    Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
    Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
    Witt RL
    Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.
    Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; Hodak SP; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
    Cancer; 2014 Dec; 120(23):3627-34. PubMed ID: 25209362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative Role of RAS or BRAF K601E in the Guidance of Surgery for Indeterminate Thyroid Nodules.
    Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
    World J Surg; 2020 Jul; 44(7):2264-2271. PubMed ID: 32227276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. American College of Radiology thyroid imaging report and data system combined with K-RAS mutation improves the management of cytologically indeterminate thyroid nodules.
    Wu H; Zhang B; Cai G; Li J; Gu X
    PLoS One; 2019; 14(7):e0219383. PubMed ID: 31295281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
    Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
    Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology.
    Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
    Thyroid; 2015 Nov; 25(11):1217-23. PubMed ID: 26356635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
    Jug RC; Datto MB; Jiang XS
    Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative detection of RAS mutation may guide extent of thyroidectomy.
    Patel SG; Carty SE; McCoy KL; Ohori NP; LeBeau SO; Seethala RR; Nikiforova MN; Nikiforov YE; Yip L
    Surgery; 2017 Jan; 161(1):168-175. PubMed ID: 27863786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical performance of a next-generation sequencing assay (ThyroSeq v2) in the evaluation of indeterminate thyroid nodules.
    Taye A; Gurciullo D; Miles BA; Gupta A; Owen RP; Inabnet WB; Beyda JN; Marti JL
    Surgery; 2018 Jan; 163(1):97-103. PubMed ID: 29154079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.